论文部分内容阅读
目的分析肺表面活性物质治疗新生儿呼吸窘迫综合症临床疗效。方法回顾分析2005年1月至2011年6月我院新生儿科收治的NRDS患儿308例,治疗组154例(基础治疗加用肺表面活性物质),对照组154例(基础治疗)。结果两组患儿临床疗效比较,治疗组治疗效果明显优于对照组。治疗组呼吸困难缓解时间(5.6±2.2)d较对照组(9.3±3.6)d短(P<0.01);治疗组发绀缓解时间(12.5±3.6)d较对照组(18.4±4.1)d短(P<0.05);治疗组胸片恢复时间(1.3±0.5)d较对照组(3.0±1.2)d短(P<0.01);治疗组住院时间(21±16)d较对照组(28±18)d短(P<0.05)。结论治疗组能够明显提高NRDS患儿治愈率,降低死亡率,减短患儿临床症状缓解时间及住院时间。
Objective To analyze the clinical efficacy of pulmonary surfactant in the treatment of neonatal respiratory distress syndrome. Methods A retrospective analysis of 308 neonates with NRDS admitted to our hospital from January 2005 to June 2011 was conducted. There were 154 cases in the treatment group (basic therapy plus pulmonary surfactant) and 154 cases in the control group (basic treatment). Results The clinical efficacy of two groups of children compared with the treatment group was significantly better than the control group. The treatment group had a shorter duration of respiratory distress (5.6 ± 2.2 days) than that of the control group (9.3 ± 3.6 days) (P <0.01). The treatment group had a shorter duration of cyanosis (12.5 ± 3.6 days) than the control group (18.4 ± 4.1 days) P <0.05). The recovery time of the chest radiograph in the treatment group (1.3 ± 0.5) d was shorter than that in the control group (3.0 ± 1.2 d) (P <0.01) ) d short (P <0.05). Conclusion The treatment group can significantly improve the cure rate of NRDS children, reduce the mortality rate and shorten the clinical symptoms and hospitalization time of children.